FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894595464> ?p ?o ?g. }

• W2894595464 endingPage "2082" @default.
• W2894595464 startingPage "2074" @default.
• W2894595464 abstract "Abstract Background Atopic dermatitis ( AD ) is a common inflammatory skin disease in both adults and children. Whilst topical calcineurin inhibitors ( TCI s), tacrolimus ointment and pimecrolimus cream, have proven efficacy for the treatment of AD , it is important to involve experts to obtain their opinion on its optimal treatment. Objective Using a modified Delphi approach, this project aimed to generate consensus amongst experts on the use of TCI s in the treatment of AD , with a focus on the differentiation between tacrolimus and pimecrolimus. Methods Six expert dermatologists from different European countries participated in this project based on their experience with AD and its treatment, which was evaluated by literature analysis and expert opinion. Consensus amongst the experts was generated using a modified Delphi approach, consisting of three distinct phases, during which a web meeting (June 2017), two online rounds of blinded Delphi voting (July–September 2017) and a face‐to‐face meeting (November 2017) were conducted. The consensus statements concerned two main topics: (i) Background of AD ; and (ii) TCI s in AD . Hot topics in the treatment of AD not supported by meta‐analysis, clinical trials or large observational studies were also discussed based on clinical experience. Results In total, 25 consensus statements were defined and validated: eight statements on the general background of AD and 17 statements on the use of TCI s in AD , including their mechanism of action and therapeutic indications in AD , efficacy in adult and paediatric AD patients, pharmacokinetics, incidence of adverse events and safety concerns. Hot topics on the use of TCI s for the treatment of AD included cream vs. ointment, dosages, TCI s contact allergy, burning sensation management, superinfection and vaccination concerns. Conclusion Topical calcineurin inhibitors are a suitable therapy for AD , and selection of the specific TCI should be based on factors which differentiate tacrolimus from pimecrolimus." @default.
• W2894595464 created "2018-10-12" @default.
• W2894595464 creator A5016449107 @default.
• W2894595464 creator A5025271629 @default.
• W2894595464 creator A5046460993 @default.
• W2894595464 creator A5048150526 @default.
• W2894595464 creator A5061979600 @default.
• W2894595464 creator A5087670282 @default.
• W2894595464 date "2018-11-06" @default.
• W2894595464 modified "2023-10-10" @default.
• W2894595464 title "Position statement: topical calcineurin inhibitors in atopic dermatitis" @default.
• W2894595464 cites W1554492313 @default.
• W2894595464 cites W1564735183 @default.
• W2894595464 cites W1573229530 @default.
• W2894595464 cites W1574078569 @default.
• W2894595464 cites W1889663809 @default.
• W2894595464 cites W1963597151 @default.
• W2894595464 cites W1970993308 @default.
• W2894595464 cites W1975199072 @default.
• W2894595464 cites W1982670399 @default.
• W2894595464 cites W1988028898 @default.
• W2894595464 cites W1989386010 @default.
• W2894595464 cites W1992880428 @default.
• W2894595464 cites W2013264166 @default.
• W2894595464 cites W2014666581 @default.
• W2894595464 cites W2019019272 @default.
• W2894595464 cites W2032219973 @default.
• W2894595464 cites W2035754178 @default.
• W2894595464 cites W2044053588 @default.
• W2894595464 cites W2063194908 @default.
• W2894595464 cites W2078065826 @default.
• W2894595464 cites W2084224801 @default.
• W2894595464 cites W2098153821 @default.
• W2894595464 cites W2116671089 @default.
• W2894595464 cites W2116889630 @default.
• W2894595464 cites W2117359358 @default.
• W2894595464 cites W2132660491 @default.
• W2894595464 cites W2142327072 @default.
• W2894595464 cites W2142463775 @default.
• W2894595464 cites W2146191214 @default.
• W2894595464 cites W2306524933 @default.
• W2894595464 cites W2365074602 @default.
• W2894595464 cites W2566687596 @default.
• W2894595464 cites W2599863631 @default.
• W2894595464 cites W2611252451 @default.
• W2894595464 cites W2616044878 @default.
• W2894595464 cites W2725018603 @default.
• W2894595464 cites W2738467603 @default.
• W2894595464 cites W2762247452 @default.
• W2894595464 cites W2766454055 @default.
• W2894595464 cites W2771123080 @default.
• W2894595464 cites W4361868722 @default.
• W2894595464 doi "https://doi.org/10.1111/jdv.15272" @default.
• W2894595464 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30288799" @default.
• W2894595464 hasPublicationYear "2018" @default.
• W2894595464 type Work @default.
• W2894595464 sameAs 2894595464 @default.
• W2894595464 citedByCount "22" @default.
• W2894595464 countsByYear W28945954642018 @default.
• W2894595464 countsByYear W28945954642019 @default.
• W2894595464 countsByYear W28945954642020 @default.
• W2894595464 countsByYear W28945954642021 @default.
• W2894595464 countsByYear W28945954642022 @default.
• W2894595464 countsByYear W28945954642023 @default.
• W2894595464 crossrefType "journal-article" @default.
• W2894595464 hasAuthorship W2894595464A5016449107 @default.
• W2894595464 hasAuthorship W2894595464A5025271629 @default.
• W2894595464 hasAuthorship W2894595464A5046460993 @default.
• W2894595464 hasAuthorship W2894595464A5048150526 @default.
• W2894595464 hasAuthorship W2894595464A5061979600 @default.
• W2894595464 hasAuthorship W2894595464A5087670282 @default.
• W2894595464 hasBestOaLocation W28945954642 @default.
• W2894595464 hasConcept C105795698 @default.
• W2894595464 hasConcept C128057223 @default.
• W2894595464 hasConcept C141071460 @default.
• W2894595464 hasConcept C142724271 @default.
• W2894595464 hasConcept C16005928 @default.
• W2894595464 hasConcept C177713679 @default.
• W2894595464 hasConcept C197934379 @default.
• W2894595464 hasConcept C23131810 @default.
• W2894595464 hasConcept C2776028589 @default.
• W2894595464 hasConcept C2778329239 @default.
• W2894595464 hasConcept C2909675724 @default.
• W2894595464 hasConcept C2911091166 @default.
• W2894595464 hasConcept C3020580240 @default.
• W2894595464 hasConcept C33923547 @default.
• W2894595464 hasConcept C60641444 @default.
• W2894595464 hasConcept C71924100 @default.
• W2894595464 hasConcept C98274493 @default.
• W2894595464 hasConceptScore W2894595464C105795698 @default.
• W2894595464 hasConceptScore W2894595464C128057223 @default.
• W2894595464 hasConceptScore W2894595464C141071460 @default.
• W2894595464 hasConceptScore W2894595464C142724271 @default.
• W2894595464 hasConceptScore W2894595464C16005928 @default.
• W2894595464 hasConceptScore W2894595464C177713679 @default.
• W2894595464 hasConceptScore W2894595464C197934379 @default.
• W2894595464 hasConceptScore W2894595464C23131810 @default.
• W2894595464 hasConceptScore W2894595464C2776028589 @default.

• next